“What’s New Doc?” in GU Cancer
Join us for insightful updates on the forefront of genitourinary (GU) cancer research with our new series, “What’s New Doc?” in GU Cancer. Each week, experts in the field will share comprehensive information and provide fresh perspectives on the latest data, offering valuable insights into GU cancer treatment and research.
Explore a diverse range of cutting-edge communication as we bring you the most recent advancements in GU cancer research. Stay tuned for weekly updates that promise to enhance your understanding of the evolving landscape in GU cancer treatment.
Professor Vulsteke from Maria Middelares Gent will discuss the SunRISE-1 study, presented at ESMO2023. This study is centred on NMIBC, diverging from the typical purview of urologists, as it excludes metastatic urogenital cancer and perioperative conditions.
The SunRISE-1 trial employs
In the primary analysis of the CLEAR study, the combination of lenvatinib and pembrolizumab (len-pem) demonstrated a statistically significant enhancement in PFS and OS when compared to sunitinib among patients with advanced renal cell carcinoma (aRCC). The recently available four-year
Professor Vulsteke is a principal investigator in the EV-302 trial, one of the most noteworthy studies presented at ESMO2023. This trial investigates the first-line treatment efficacy of the combined application of enfortumab vedotin (EV) and pembrolizumab (P) compared to the